Progression and survival in Parkinson's disease with subthalamic nucleus stimulation

Acta Neurol Scand. 2014 Nov;130(5):292-8. doi: 10.1111/ane.12224. Epub 2014 Feb 4.

Abstract

Background: Treatment for Parkinson's disease (PD) is symptomatic. Surgical treatment with continuous high-frequency stimulation of the subthalamic nucleus (STN-DBS) is established as a safe symptomatic treatment with long-term beneficial effects. It has been postulated that STN-DBS could halt the progression of PD through a disease modifying or neuroprotective effect.

Objective: To investigate the postulated disease modifying or neuroprotective effect of STN-DBS by comparing the rate of deterioration of parkinsonism and mortality over time in two selected and matched groups of patients with PD with and without surgery.

Methods: Group A was derived from all patients who received STN-DSB surgery at Oslo University Hospital, from January 2001 to December 2007. Group B was derived from a prevalence study of PD in the Stavanger area of Western Norway in 1993. The two groups were individually matched and the disease progression measured by Unified Parkinson's Disease Rating Scale-motor scores, and the mortality was compared.

Results: The mean annual change based on baseline and last observation scores in individually matched groups was 0.97 (SD = 3.57) for the surgery group and 1.04 (SD = 3.33) for the controls and thus not significantly different, F(1, 104) = .21, P = 0.89. The long-term mortality was also similar in the two groups during long-term follow-up, hazard ratio = 1.76, CL 0.91-3.40, P = 0.091.

Conclusion: This study gives no support to a postulated disease modifying or neuroprotective effect of STN-DBS in patients with PD.

Keywords: Parkinson's disease; deep brain stimulation of the subthalamic nucleus; modulation; mortality; progression.

MeSH terms

  • Aged
  • Deep Brain Stimulation / methods*
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Norway / epidemiology
  • Parkinson Disease / mortality*
  • Parkinson Disease / therapy*
  • Proportional Hazards Models
  • Subthalamic Nucleus / physiology